Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

NCT00867568 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT00867568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00867568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Lead sponsor
Giselle Sholler
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2009
Completion date
February 29, 2016
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

medulloblastoma, neuroblastoma, relapse